By Ivana Magovcevic-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC From academic research, patent law, business development, to being a CEO, all my experiences have taught me two things. First, one cannot do

It’s biotech armageddon out there: with massive value destruction across public stocks, it’s clearly the worst market backdrop in over 20 years. Nothing like this pullback has happened in recent memory. This is way worse than the short “sky is

By Robert Clarke, CEO of Kinaset, as part of the From The Trenches feature of LifeSciVC. Although I intend to shy away from the cult of celebrity, a recent clip from Tom Hanks resonated with me regarding the current state

By Jonathan Montagu, CEO and founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. White Hat Hackers, sometimes called “ethical hackers,” are individuals that work to find and fix security problems in a system by

By Deanna Petersen, CBO of AVROBIO, and Ted Tanaka, consultant with Tanaka International LLC, as part of the From The Trenches feature of LifeSciVC Imagine yourself setting out to do business in Japan. You step off the plane, check into

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC 2022 has brought unique challenges for growing companies.  Capital markets, shifting regulatory winds and other emergent forces are driving tough decisions on programs,

By René Russo, CEO of Xilio Therapeutics, as part of the From The Trenches feature of LifeSciVC I had the opportunity to witness true courage as I met Chrissy Harding several times before she passed away from advanced lung cancer.

By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC  A couple of years ago, my husband returned from a business trip with a random gift for me. He was running through an airport

By Andrea DiMella, VP and Head of Talent at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Like many of you, I’m a consumer of biotech industry news. Multiple times of day I scour BioCentury, STAT,

Another day, another “restructuring” – there’s been a flurry of press releases recently using phrases like “exploring strategic alternatives”, “extending the cash runway”, and “de-prioritizing” certain R&D programs. These announcements are obviously responses to the tough market environment. In every

By Natalie Holles, CEO of Third Harmonic Bio, as part of the From The Trenches feature of LifeSciVC Our company recently launched out of stealth with a trade media campaign in the usual outlets, which felt great until one article

While the pace of startup formation in biotech has been accelerating over the past decade, early signs suggest the malaise in the markets is finding its way back into the venture creation ecosystem. Startups get formed, often in stealth, and